Michèle Masquelier

A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate: in vitro and in vivo studies.

A. Trouet, Michèle Masquelier, R. Baurain et al. · Proceedings of the National Academy of Sciences · 1982 · 233 citations

Free Dnr, Glycobiology, Immunology +22

Uptake of low density lipoproteins by human leukemic cells in vivo: relation to plasma lipoprotein levels and possible relevance for selective chemotherapy.

Sigurd Vitols, Bo Angelin, S Ericsson et al. · Proceedings of the National Academy of Sciences · 1990 · 128 citations

Hyperlipidemia, Myeloid Neoplasia, Hematological Malignancy +18

Low-density lipoprotein as a carrier of antitumoral drugs: in vivo fate of drug-human low-density lipoprotein complexes in mice.

Michèle Masquelier, Sigurd Vitols, Curt Peterson · PubMed · 1986 · 92 citations

Low-density Lipoprotein, Medicinal Chemistry, Ldl Receptor Activity +16

Amino acid and dipeptide derivatives of daunorubicin. 1. Synthesis, physicochemical properties, and lysosomal digestion

Michèle Masquelier, R. Baurain, André Trouet · Journal of Medicinal Chemistry · 1980 · 70 citations

Low density lipoprotein for delivery of a water-insoluble alkylating agent to malignant cells. In vitro and in vivo studies of a drug-lipoprotein complex

Sigurd Vitols, K Söderberg-Reid, Michèle Masquelier et al. · British Journal of Cancer · 1990 · 66 citations · Full text

Drug Targeting, Polymer-drug Conjugate, Medicine +6